Business Context and Reporting Period
This Form 8-K Current Report was filed by IOVANCE BIOTHERAPEUTICS, INC. (formerly Lion Biotechnologies, Inc.) on June 27, 2017. The filing documents a corporate name change and associated administrative updates effective as of the report date.
Key Financial Metrics
This filing is a current report regarding corporate governance and identity changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. No financial metrics are provided in this document.
Material Changes
- Corporate Name Change: The company changed its name from "Lion Biotechnologies, Inc." to "Iovance Biotherapeutics, Inc." via an Amendment to its Certificate of Incorporation filed with the Delaware Secretary of State.
- Bylaws Amendment: The company amended its Bylaws to reflect the new corporate name.
- Trading Symbol Update: Effective at the market open on June 28, 2017, the Nasdaq Global Market trading symbol changed from "LBIO" to "IOVA".
- CUSIP Number: A new CUSIP number, 462260100, was assigned to the common stock.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or management commentary regarding future performance. It notes that existing stock certificate holders do not need to take action to update their certificates to reflect the new name. The press release announcing the change is incorporated by reference but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the new trading symbol IOVA on the Nasdaq Global Market.
- Confirm the new CUSIP number 462260100 for trading and settlement purposes.
- Review the attached press release (Exhibit 99.1) for strategic rationale behind the rebranding.
- Check subsequent filings (e.g., 10-Q or 10-K) for financial performance data, as this 8-K contains none.